Cargando…

Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression

Major depressive disorder is one of the most common and debilitating psychiatric disorders. Some of the motivational symptoms of depression, such anergia (lack of self-reported energy) and fatigue are relatively resistant to traditional treatments such as serotonin uptake inhibitors. Thus, new pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Cruz, Laura, Salamone, John D., Correa, Mercè
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992708/
https://www.ncbi.nlm.nih.gov/pubmed/29910727
http://dx.doi.org/10.3389/fphar.2018.00526
_version_ 1783330082499067904
author López-Cruz, Laura
Salamone, John D.
Correa, Mercè
author_facet López-Cruz, Laura
Salamone, John D.
Correa, Mercè
author_sort López-Cruz, Laura
collection PubMed
description Major depressive disorder is one of the most common and debilitating psychiatric disorders. Some of the motivational symptoms of depression, such anergia (lack of self-reported energy) and fatigue are relatively resistant to traditional treatments such as serotonin uptake inhibitors. Thus, new pharmacological targets are being investigated. Epidemiological data suggest that caffeine consumption can have an impact on aspects of depressive symptomatology. Caffeine is a non-selective adenosine antagonist for A(1)/A(2A) receptors, and has been demonstrated to modulate behavior in classical animal models of depression. Moreover, selective adenosine receptor antagonists are being assessed for their antidepressant effects in animal studies. This review focuses on how caffeine and selective adenosine antagonists can improve different aspects of depression in humans, as well as in animal models. The effects on motivational symptoms of depression such as anergia, fatigue, and psychomotor slowing receive particular attention. Thus, the ability of adenosine receptor antagonists to reverse the anergia induced by dopamine antagonism or depletion is of special interest. In conclusion, although further studies are needed, it appears that caffeine and selective adenosine receptor antagonists could be therapeutic agents for the treatment of motivational dysfunction in depression.
format Online
Article
Text
id pubmed-5992708
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59927082018-06-15 Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression López-Cruz, Laura Salamone, John D. Correa, Mercè Front Pharmacol Pharmacology Major depressive disorder is one of the most common and debilitating psychiatric disorders. Some of the motivational symptoms of depression, such anergia (lack of self-reported energy) and fatigue are relatively resistant to traditional treatments such as serotonin uptake inhibitors. Thus, new pharmacological targets are being investigated. Epidemiological data suggest that caffeine consumption can have an impact on aspects of depressive symptomatology. Caffeine is a non-selective adenosine antagonist for A(1)/A(2A) receptors, and has been demonstrated to modulate behavior in classical animal models of depression. Moreover, selective adenosine receptor antagonists are being assessed for their antidepressant effects in animal studies. This review focuses on how caffeine and selective adenosine antagonists can improve different aspects of depression in humans, as well as in animal models. The effects on motivational symptoms of depression such as anergia, fatigue, and psychomotor slowing receive particular attention. Thus, the ability of adenosine receptor antagonists to reverse the anergia induced by dopamine antagonism or depletion is of special interest. In conclusion, although further studies are needed, it appears that caffeine and selective adenosine receptor antagonists could be therapeutic agents for the treatment of motivational dysfunction in depression. Frontiers Media S.A. 2018-06-01 /pmc/articles/PMC5992708/ /pubmed/29910727 http://dx.doi.org/10.3389/fphar.2018.00526 Text en Copyright © 2018 López-Cruz, Salamone and Correa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
López-Cruz, Laura
Salamone, John D.
Correa, Mercè
Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title_full Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title_fullStr Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title_full_unstemmed Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title_short Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
title_sort caffeine and selective adenosine receptor antagonists as new therapeutic tools for the motivational symptoms of depression
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992708/
https://www.ncbi.nlm.nih.gov/pubmed/29910727
http://dx.doi.org/10.3389/fphar.2018.00526
work_keys_str_mv AT lopezcruzlaura caffeineandselectiveadenosinereceptorantagonistsasnewtherapeutictoolsforthemotivationalsymptomsofdepression
AT salamonejohnd caffeineandselectiveadenosinereceptorantagonistsasnewtherapeutictoolsforthemotivationalsymptomsofdepression
AT correamerce caffeineandselectiveadenosinereceptorantagonistsasnewtherapeutictoolsforthemotivationalsymptomsofdepression